OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 136 filers reported holding OCULAR THERAPEUTIX INC in Q2 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $37 | +2.8% | 5,384 | +37.9% | 0.00% | – |
| Q1 2024 | $36 | -26.5% | 3,903 | -64.8% | 0.00% | – |
| Q4 2023 | $49 | +32.4% | 11,087 | -6.7% | 0.00% | – |
| Q3 2023 | $37 | -39.3% | 11,881 | 0.0% | 0.00% | – |
| Q2 2023 | $61 | +7.0% | 11,881 | +10.6% | 0.00% | – |
| Q1 2023 | $57 | +62.9% | 10,744 | -13.1% | 0.00% | – |
| Q4 2022 | $35 | -99.9% | 12,360 | 0.0% | 0.00% | – |
| Q3 2022 | $51,000 | +4.1% | 12,360 | +1.6% | 0.00% | – |
| Q2 2022 | $49,000 | -21.0% | 12,164 | -2.8% | 0.00% | – |
| Q1 2022 | $62,000 | -67.0% | 12,519 | -53.7% | 0.00% | -100.0% |
| Q4 2021 | $188,000 | +36.2% | 27,064 | +96.3% | 0.00% | 0.0% |
| Q3 2021 | $138,000 | -32.7% | 13,785 | -4.8% | 0.00% | -50.0% |
| Q2 2021 | $205,000 | +21.3% | 14,475 | +40.9% | 0.00% | -66.7% |
| Q1 2021 | $169,000 | -23.5% | 10,272 | -3.7% | 0.01% | -25.0% |
| Q4 2020 | $221,000 | – | 10,662 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,784,850 | $15,064,000 | 62.56% |
| Versant Venture Management, LLC | 2,215,384 | $8,817,228,000 | 4.36% |
| SV Health Investors, LLC | 628,236 | $2,500,000 | 1.54% |
| DELTEC ASSET MANAGEMENT LLC | 724,747 | $2,885,000 | 0.80% |
| Endurant Capital Management LP | 232,727 | $926,000 | 0.49% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $1,011,000 | 0.15% |
| JGP Global Gestao de Recursos Ltda. | 12,568 | $50,000 | 0.06% |
| Man Group plc | 1,187,508 | $4,726,000 | 0.02% |
| Dynamic Technology Lab Private Ltd | 21,077 | $84,000 | 0.02% |
| NewEdge Advisors, LLC | 36,250 | $144,000 | 0.01% |